富马酸二甲酯治疗复发难治性皮肤T细胞淋巴瘤:一项多中心2期研究
这项多中心2期研究评估口服富马酸二甲酯治疗25例Ib至IV期皮肤T细胞淋巴瘤患者24周的安全性和疗效。23例可评估皮肤反应的患者中7例(30.4%)mSWAT评分下降超过50%,皮肤和血液高肿瘤负荷者应答最佳,总体耐受性良好,多为轻度副作用。
要点
- 23例可评估患者中7例(30.4%)皮肤mSWAT评分下降超过50%。
- 皮肤和血液高肿瘤负荷患者对富马酸二甲酯治疗应答最佳。
- 总体耐受性良好,副作用多为轻度。
核心结论
- 富马酸二甲酯是皮肤T细胞淋巴瘤有效且耐受性极佳的治疗选择,有待3期研究、真实世界患者管理及联合治疗中进一步评估。
研究设计与样本
- 多中心2期研究,评估口服富马酸二甲酯治疗25例Ib至IV期皮肤T细胞淋巴瘤患者,疗程24周(EudraCT编号2014-000924-11/NCT编号NCT02546440)。
- 研究终点为安全性和疗效。
主要发现
- 23例可评估皮肤反应的患者中7例(30.4%)mSWAT评分下降超过50%。
- 皮肤和血液高肿瘤负荷患者对富马酸二甲酯治疗应答最佳。
- 富马酸二甲酯改善部分患者瘙痒,但总体未达显著。
- 血液应答不一,但证实了富马酸二甲酯在血液中的NF-κB抑制机制。
- 总体耐受性良好,副作用多为轻度。
临床怎么用
- 作者认为富马酸二甲酯是皮肤T细胞淋巴瘤有效且耐受性极佳的治疗选择,有待3期研究、真实世界患者管理及联合治疗中进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted therapies for cutaneous T-cell lymphoma (CTCL) are limited and curative approaches are lacking. Furthermore, relapses and drug induced side effects are major challenges in the therapeutic management of patients with CTCL, creating an urgent need for new and effective therapies. Pathologic constitutive NF-κB activity leads to apoptosis resistance in CTCL cells and, thus, represents a promising therapeutic target in CTCL. In a preclinical study we showed the potential of dimethyl fumarate (DMF) to block NF-κB and, specifically, kill CTCL cells. To translate these findings to applications in a clinical setting, we performed a multicentric phase 2 study evaluating oral DMF therapy in 25 patients with CTCL stages Ib to IV over 24 weeks (EudraCT number 2014-000924-11/NCT number NCT02546440). End points were safety and efficacy. We evaluated skin involvement (using a modified severity weighted assessment tool [mSWAT]), pruritus, quality of life, and blood involvement, if applicable, as well as translational data. Upon skin analysis, 7 of 23 (30.4%) patients showed a response with >50% reduction in the mSWAT score. Patients with high tumor burden in the skin and blood responded best to DMF therapy. Although not generally significant, DMF also improved pruritus in several patients. Response in the blood was mixed, but we confirmed the NF-κB-inhibiting mechanism of DMF in the blood. The overall tolerability of the DMF therapy was very favorable, with mostly mild side effects. In conclusion, our study presents DMF as an effective and excellently tolerable therapeutic option in CTCL to be further evaluated in a phase 3 study or real-life patient care as well as in combination therapies. This trial was registered at www.clinicaltrials.gov as #NCT02546440.
引用
- Nicolay JP, Melchers S, Albrecht JD, et al. Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study. Blood. 2023. PMID: 37217183. doi:10.1182/blood.2022018669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。